Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Key Points

• Royal Bank of Canada cut its ACADIA Pharmaceuticals stake by 23.3% in the first quarter, selling 67,699 shares and retaining 223,155 shares worth about $4.97 million. Institutional investors still own 96.71% of the company.
• ACADIA reported quarterly earnings of $0.18 per share, beating estimates of $0.07, while revenue rose 16.4% year over year to $308 million. Shares opened at $29.45, near their 12-month high.
• Analyst sentiment remains favorable: Needham raised its price target to $41, and ACADIA has a “Moderate Buy” consensus rating with an average target of $33.69. Growth expectations for Daybue and Nuplazid support the outlook, though upcoming RADIANT clinical data remains a potential risk.

Royal Bank of Canada lowered its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 23.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 223,155 shares of the biopharmaceutical company's stock after selling 67,699 shares during the quarter. Royal Bank of Canada owned about 0.13% of ACADIA Pharmaceuticals worth $4,969,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 386 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at approximately $26,000. Transamerica Financial Advisors LLC increased its holdings in ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 1,005 shares during the last quarter. Federated Hermes Inc. raised its position in ACADIA Pharmaceuticals by 277.5% in the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company's stock valued at $43,000 after purchasing an additional 1,185 shares during the period. Finally, Leonteq Securities AG purchased a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $52,000. Hedge funds and other institutional investors own 96.71% of the company's stock.

ACADIA Pharmaceuticals Trading Up 0.1%

NASDAQ:ACAD opened at $29.45 on Thursday. The firm has a market cap of $5.07 billion, a PE ratio of 13.27, a price-to-earnings-growth ratio of 23.16 and a beta of 0.81. The stock has a fifty day moving average price of $24.88 and a 200 day moving average price of $23.31. ACADIA Pharmaceuticals Inc. has a 12-month low of $19.69 and a 12-month high of $29.85.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. The company had revenue of $308.00 million for the quarter, compared to the consensus estimate of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.ACADIA Pharmaceuticals's revenue was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.16 EPS. Equities analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.59 EPS for the current year.

ACADIA Pharmaceuticals News Roundup

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Needham raised its price target on ACADIA from $38 to $41 and maintained a “Buy” rating, implying substantial upside from the recent trading level. The higher target reflects increased confidence in the company’s growth outlook. Benzinga
• Positive Sentiment: Citi also initiated or reiterated a Buy view on ACADIA, adding to the favorable analyst sentiment surrounding the company. Citi Buy Recommendation
• Positive Sentiment: Analysts expect Daybue and Nuplazid growth to support ACADIA’s revenue and earnings expansion. The company’s recent quarterly performance also showed year-over-year revenue growth and earnings above consensus estimates, reinforcing the growth narrative. Daybue and Nuplazid Growth Outlook
• Positive Sentiment: ACADIA shares reached a new 12-month high, indicating strong momentum and heightened market interest. The stock is trading above both its 50-day and 200-day moving averages. ACADIA 12-Month High
• Neutral Sentiment: The Q2 earnings call highlighted growth momentum and the company’s commercial opportunities, though investors will continue monitoring execution, product adoption, and upcoming catalysts. ACADIA Earnings Call Highlights
• Neutral Sentiment: Reported short interest was zero, according to the available data, suggesting no measurable short-selling pressure but providing limited additional trading insight.
• Negative Sentiment: RADIANT clinical data introduces uncertainty. While successful results could provide another growth driver, disappointing data could pressure the shares and offset the current analyst optimism. RADIANT Data Risk

Wall Street Analyst Weigh In

Several research analysts have recently commented on ACAD shares. Needham & Company LLC raised their price target on ACADIA Pharmaceuticals from $38.00 to $41.00 and gave the stock a "buy" rating in a research report on Wednesday. Royal Bank Of Canada increased their target price on ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 5th. Bank of America restated a "buy" rating and set a $14.50 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday, July 29th. Citizens Jmp lifted their target price on ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the company a "market outperform" rating in a research report on Wednesday, August 5th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $33.69.

Insider Transactions at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 14,292 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $29.22, for a total value of $417,612.24. Following the completion of the transaction, the executive vice president owned 67,828 shares in the company, valued at $1,981,934.16. The trade was a 17.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the business's stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total transaction of $432,660.54. Following the transaction, the executive vice president owned 18,994 shares of the company's stock, valued at $496,313.22. This trade represents a 46.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 42,100 shares of company stock valued at $1,134,287. 26.20% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source